Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model.
Diabetes mellitus is a metabolic disease characterized by hyperglycemia (American Diabetes Association 2011; Silvana and Rifa'i 2015) . International Diabetes Federation (2013) have stated that there are 382 million adults (8.3%) suffering from diabetes and this number is expected to be increasing until 592 million within 25 years. The high prevalence of diabetes can increase atherosclerosis prevalence because it is a major risk factor for atherosclerosis development and clinical manifestations, including coronary artery disease, stroke, and peripheral vascular disease (Chait and Bornfeldt 2009; Heriansyah et al. 2015) .
Hyperglycemia induces most of the changes at cellular level in vascular tissue that potentially accelerate atherosclerosis process (Aronson and Rayfield 2002) . Hyperglycemia also leads to an impairment in nitric oxide (NO) production (Avogaro et al. 2011) . Inducible NOS (iNOS) is one of NO synthase isoform. Atherosclerosis is associated with iNOS expression increase (Fukuchi and Giaid 1999) influencing the cellular adhesion molecules (CAM) interaction (Galkina and Ley 2007) . In atherosclerosis, high low-density lipoprotein (LDL) level can increase free radical that is vulnerable to various oxidative process and triggered pro-inflammatory cells recruitment and adherence . Atherosclerosis affects discrete portion of the blood vessels, such as vessel curvature and bifurcation. These sections are marked by disturbed oscillatory flow, which induces upregulation of the adhesion molecules pro-inflammatory, such as intercellular adhesion molecule 1 (ICAM-1) (Galkina and Ley 2007) .
Low density lipoprotein (LDL), oxidized LDL (ox-LDL), and free fatty acid (FFA) level have been shown to be increased in type 2 diabetes mellitus (T2DM) (Turan and Dhalla 2014) . LDL cholesterol is harmful because of lipid peroxidation process (auto-oxidation) (Wihastuti et al. 2014) . LDL is closely related to enzyme lipoprotein-associated phospholipase A2 (Lp-PLA 2 ). This enzyme is originally known as a platelet-activating factor acetylhydrolase (PAF-AH), which has two biological activities such as inactivation of PAF-AH pro-inflammatory mediators and hydrolyzing the oxidative modified polyunsaturated fatty acids that produce lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (OxNE-FA). OxNEFA has chemotactic activity of monocytes and LysoPC is involved in the regulation of inflammatory mediators, including cytokines, adhesion molecules, and MCP-1 (Carlquist et al. 2007) .
Darapladib was known as a specific inhibitor of Lp-PLA 2 and has been already developed as a drug for atherosclerosis (Thompson et al. 2013 ). The Lp-PLA 2 role in the atherogenesis is still ambiguous . There are few studies on darapladib effects in atherosclerosis. One of them is the research conducted by Heriansyah et al. (2016) . These authors have shown that darapladib administration can reduce oxLDL and foam cells amount.
Therefore, the aim of this study was to investigate the effect of darapladib on foam cells number, and iNOS, and ICAM-1 expression in aorta in early stages of atherosclerosis in Sprague-Dawley T2DM rat model.
Materials and Methods
Animals and treatment. Four-week-old male Sprague-Dawley rats with 150-200 g of body weight (b.w.) were used in this study. Animals were obtained from Bogor Agricultural University, Bogor, Indonesia. Ethical approval for the animal treatment and experimental processes in this study were obtained from the Animal Care and Use Committee Brawijaya University (400/EC/KEPK/10/2016). Rats were divided into 3 main groups: control, type 2 diabetes mellitus (T2DM), and T2DM with darapladib administration (T2DM-DP). Each group was exposed to 2 serials time treatments: 8-week and 16-week. Two T2DM groups were fed with high fat diet (HFD) and one of them also intraperitoneally (i.p.) injected with low dose of streptozotocin (STZ; 35 mg/kg b.w.). STZ was diluted with 1 ml of citrate buffer as vehicle/injection. Darapladib was obtained from Glaxo Smith Kline. Darapladib (20 mg/kg b.w.) was administered orally once a day. Darabadib was diluted with 5 ml of PZ Solution (0.9% NaCl) as vehicle per rat per daily oral administration. Normal rats' food contained 3.43 kcal/g total energy calories, while the HFD contained 5.29 kcal/g total calories. Thirty grams of food were given for each rat every day. Body weights of rats were measured before and after DM induction. The measurement of biochemical parameters was performed at the Central Laboratory of Biological Sciences, Brawijaya University (Malang, East Java, Indonesia).
Blood glucose measurement. STZ (35 mg/kg b.w.) was administered before the first blood glucose measurement to induce T2DM. T2DM was diagnosed after blood glucose level measurement using GlucoDR blood glucose test meter (All Medicus Co. Ltd, Dongangu, Anyang-si, Korea). T2DM was diagnosed after obtaining fasting blood glucose levels >126 mg/dL in rats.
Insulin resistance measurement. Plasma insulin levels were measured using Rat INS (insulin) ELISA kit (Cat. No. E-EL-R2466) from ElabScience. Plasma insulin levels were converted into IU/L. WHO formula was used by dividing the result with 0.0347, as 1 IU is equivalent with 0.0347 mg/L (Burns et al. 2010) . Insulin resistance can be measured with HOMA-IR (homeostatic model assessment-insulin resistance) formula especially in rats, which required some data, such as fasting glucose and plasma insulin levels by the following formula (Van Dijk et al. 2013 Interpretation of HOMA-IR calculation in rats is if the result >1.716 when it can be categorized as insulin resistance with 83.87% sensitivity and 80.56% specificity (95% confidence interval) (Cacho et al. 2008) .
Lipid profile measurement. Lipid profiles [(total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL)] were measured in rat blood serum using EnzyChrom™ kit (Cat. No EHDL-100) from BioAssay System Inc.
Foam cell measurement. The foam cells observation started with a slide preparation. The aortic tissues were stained using Oil Red O. Aortic tissues were embedded in paraffin and cut into slices of 5 µm thickness with Sakura Accu-cut SRM 200 Rotary Microtome. Then hematoxylin-eosin (HE) staining was performed. The study started with scanning of histopathological slides using a microscope at 400× magnification, viewed, and then counted using dotslide software.
iNOS and ICAM-1 expression measurement using immunofluorescence. The expression of iNOS and ICAM-1 in aortic tissue was determined by immunofluorescence. The samples were fixed with a PHEMO buffer (68 mM PIPES, 25 mM, HEPES, pH 6.9, 15 mM EGTA, 3 mM MgCl2, 10% [v/v] dimethyl sulfoxide containing 3.7% formaldehyde and 0.05% glutaraldehyde) and processed by immunofluorescence labeling with anti-rat antibody ICAM-1 using rhodamin secondary antibody (BIOS Inc., Boston, MA, USA) and anti-rabbit antibody iNOS using FITC secondary antibody. The samples that have been labeled with antibodies were incubated for 10 min at room temperature. This parameter was observed under confocal laser scanning microscopy (Olympus Corporation, Tokyo, Japan) and were quantitatively analyzed using Olympus FluoView software (version 1.7A; Olympus Corporation).
Statistical Analysis. Data were analyzed using one-way analysis of variance (ANOVA) followed by Duncan Multiple Range Test to compare each group. All the analyses were performed using SPSS statistical software, version 16.0. Value p<0.05 was considered to be statistically significant.
Results
Biochemical parameters, foam cells number, expression of iNOS and ICAM-1 in aortic tissues determined in all treatment groups are summarized in Table 1 . Induction of T2DM in Sprague-Dawley male rats after high fat diet and streptozotocin administration was confirmed by increased fasting blood glucose (>126 mg/dL), plasma insulin levels, and insulin resistance (using HOMA-IR >1.716) compared to controls after both times of treatment. Moreover, elevated levels of total cholesterol and LDL, and decreased HDL levels were measured compared to controls after both times of treatment (Table1). Darapladib administration induced a significant inhibitory effect (p<0.05) on investigated elevated biochemical parameters compared to T2DM group after both times of treatment (except LDL levels where reduced levels in T2DM rats were observed after 16-week treatment) indicating a beneficial effect of darapladib on animals Abbreviations: T2DM -type 2 diabetes mellitus; T2DM-DP -type 2 diabetes mellitus with darapladib; HDL -high-density cholesdarapladib; HDL -high-density choles-HDL -high-density cholesterol; LDL -low-density cholesterol; iNOS -inducible nitric oxide synthase; ICAM-1 -intra cellular adhesion molecule-1. Data were analyzed by one-way ANOVA and following Duncan multiple range post-test; different superscripts indicate a statistical significance.
with T2DM (Table 1) . Darapladib induced a beneficial effect on HDL levels (p<0.05) compared to T2DM group only after 8 weeks of treatment (Table 1) .
T2DM induced a significant increase (p<0.05) in the foam cells number (Figure 3) , iNOS (Figure 1 ) and ICAM-1 (Figure 2 ) expression in aortic tissues of male rats compared to controls after both times of treatment (Table1). The highest values of foam cells number, iNOS and ICAM-1 expression were seen in T2DM 16-week group (Table1). Treatment with darapladib significantly reduced (p<0.05) foam cells number (Figure 3) as well as iNOS expression (Figure 1 ) in aortic tissue of rats with T2DM after both times of treatment (Table 1) . A significant decrease (p<0.05) in ICAM-1 expression in aortic tissue was observed after darapladib treatment in rats with T2DM only after 8 weeks of the treatment (Figure 2 , Table 1 ).
Discussion
High fat diet consumption lead to an abnormal fat accumulation in muscle and liver. Lipid accumulation is related to insulin resistance. Insulin resistance in muscle leads to hepatic lipid accumulation through de novo lipogenesis. Hepatic lipid accumulation can cause hepatic insulin resistance by increasing glycogen synthesis and gluconeogenesis (Samuel and Shulman 2012) . In this study, insulin resistance and hyperglycemia were seen. Sumagin et al. (2008) have studies a possible role of ICAM-1 and leukocyte-endothelial interactions on the vascular permeability regulation. During inflammation development, there are two major events. Leukocytes interact with endothelium leading to the cell passing through the barrier created by the en- Recent study has shown a significant increase in adhesion molecule in T2DM group compared to normal (control) group. This may be caused by hyperglycemia in diabetes mellitus. Hyperglycemia can enhance the monocyte adhesion to endothelial cells (Navale and Paranjape 2013). Meanwhile, we found a decrease in ICAM-1 expression between T2DM 8-week and T2DM-DP 8-week groups (p<0.05). There was no significant decrease in T2DM 16-week and T2DM-DP 16-week groups (p>0.05), although the trend was decreasing. Decreased expression of ICAM-1 after darapladib administration is still controversial. Hu et al. (2011) have shown that darapladib only decreased the expression of VCAM-1 but not the expression of ICAM-1. Meanwhile, Wang et al. (2011) have shown that the expression of ICAM-1 in the darapladib group was lower in comparison with the positive control group, which correlates with our finding. Wang et al. (2011) have also reported that oxLDL can activate inflammation signaling pathways, such as NF-KB, MAPK, or PPAR. There is also a positive relationship between Lyso-PC in activating inflammation genes, such as iNOS, IL-1β or cyclooxygenase-2 . Darapladib administration can inhibit hydrolysis of oxLDL to LysoPC and oxNEFA and this can inhibit inflammation genes, such as iNOS.
In atherosclerosis development, LDL, macrophage and T lymphocyte can easily migrate through intima. LDL is a small and dense particle, what makes it vul- nerable to oxidation and the antioxidant decrease can cause a high production of free radicals and modified the oxidative LDL. Lp-PLA 2 is then activated by oxidized phospholipid to oxLDL. The enzyme minimalizes oxLDL modification. During this process, lysophospholipids and oxNEFA are highly produced and cause adhesion macrophage pulled to the arterial intima. Activated macrophage slowly changes into foam cells (Silva et al. 2010 ). This may be a cause of the increasing foam cells number in this study.
Darapladib, a carbon-based small molecule taken orally specifically inhibits Lp-PLA 2 at certain doses. The inhibition of Lp-PLA 2 is expected to inhibit oxidation of phospholipids in the vascular space and to reduce expression of adhesion molecules and other factors that may lead to atherosclerosis. Darapladib has been shown to reduce the content of lysophosphatidylcholine and the expression of 24 genes related to macrophage and T lymphocyte function, with a decrease them in plaque and necrotic areas (Wilensky et al. 2008) . The results of the present study showed that darapladib can decrease the foam cells number as well as iNOS and ICAM-1 expression, the markers of the atherosclerosis progression.
Conclusions
The results of the present study showed that darapladib can decrease the foam cells number, iNOS and ICAM-1 expression in aorta in early stages of the atherosclerosis in Sprague-Dawley T2DM rat model. These results indicate for a potential beneficial effect of darapladib on atherosclerosis.
The future biomedical implications our research findings may be in a form of biomarker helping detect the early stages of atherosclerosis.
